We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $1.11B
1-Year Est. Return 866.76%
This Fund
S&P 500
This Quarter Est. Return
+40.16%
1 Year Est. Return
+866.76%
3 Year Est. Return
+2,969.39%
5 Year Est. Return
+5,038.91%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
+$209M
Cap. Flow
-$52.4M
Cap. Flow %
-4.71%
Top 10 Hldgs %
78.54%
Holding
34
New
5
Increased
4
Reduced
6
Closed
7

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$35.8M
2
SMMT icon
Summit Therapeutics
SMMT
+$22.2M
3
DFTX
Definium Therapeutics
DFTX
+$12.6M
4
ANL
Adlai Nortye Group ADS
ANL
+$11.4M
5
PHVS icon
Pharvaris
PHVS
+$8.83M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$29.8M
2
KALV
KalVista Pharmaceuticals
KALV
+$29.2M
3
TERN
Terns Pharmaceuticals
TERN
+$27.9M
4
TRVI icon
Trevi Therapeutics
TRVI
+$17M
5
OCUL icon
Ocular Therapeutix
OCUL
+$9.89M

Sector Composition

Rank Sector Weight
1 Healthcare 97.93%
2 Miscellaneous 2.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$6.05B
$180M 16.14%
1,841,667
-105,000
-5% -$9.17M
DFTX
2
Definium Therapeutics
DFTX
$5.12B
$139M 12.47%
2,950,000
+510,000
+21% +$12.6M
ABVX
3
Abivax
ABVX
$10B
$132M 11.89%
993,000
+316,000
+47% +$35.8M
COGT icon
4
Cogent Biosciences
COGT
$6.03B
$90.9M 8.17%
2,350,000
– –
ALMS
5
Alumis Inc
ALMS
$1.44B
$79.7M 7.16%
2,830,700
– –
AVBP icon
6
ArriVent BioPharma
AVBP
$1.53B
$68.5M 6.15%
1,971,054
– –
TSHA icon
7
Taysha Gene Therapies
TSHA
$1.82B
$66M 5.93%
9,693,244
+833,333
+9% +$4.93M
BIOA
8
BioAge Labs
BIOA
$440M
$42.8M 3.85%
1,748,000
– –
MIRM icon
9
Mirum Pharmaceuticals
MIRM
$6.15B
$39.7M 3.57%
338,900
– –
KYMR icon
10
Kymera Therapeutics
KYMR
$9.76B
$35.5M 3.2%
310,000
-115,000
-27% -$9.88M
AKTS
11
Aktis Oncology
AKTS
$1.5B
$31M 2.78%
960,847
– –
XENE icon
12
Xenon Pharmaceuticals
XENE
$5.79B
$29.6M 2.66%
490,000
– –
ERAS icon
13
CALL
Erasca
ERAS
$5.66B
$23M 2.07%
+1,255,000
New +$17.9M
PALI icon
14
Palisade Bio
PALI
$364M
$21.5M 1.93%
10,276,317
– –
OCUL icon
15
Ocular Therapeutix
OCUL
$2.34B
$20.4M 1.83%
2,075,000
-1,091,600
-34% -$9.89M
IRON icon
16
Disc Medicine
IRON
$3.04B
$19.7M 1.78%
270,000
– –
SMMT icon
17
Summit Therapeutics
SMMT
$14B
$18.2M 1.64%
+1,250,000
New +$22.2M
PHVS icon
18
Pharvaris
PHVS
$2.47B
$15.8M 1.42%
456,721
+291,721
+177% +$8.83M
ANL
19
Adlai Nortye Group ADS
ANL
$967M
$10.7M 0.97%
+934,716
New +$11.4M
DTIL icon
20
Precision BioSciences
DTIL
$206M
$10.6M 0.95%
1,350,000
-886,732
-40% -$6.24M
DBVT
21
DBV Technologies
DBVT
$847M
$9.42M 0.85%
574,200
– –
FTH
22
Faeth Therapeutics
FTH
$1.03B
$9.03M 0.81%
+361,010
New +$8.35M
GYRE icon
23
Gyre Therapeutics
GYRE
$727M
$6.29M 0.57%
+954,416
New +$6.5M
TRVI icon
24
Trevi Therapeutics
TRVI
$2.46B
$5.87M 0.53%
315,000
-1,170,000
-79% -$17M
UNCY icon
25
Unicycive Therapeutics
UNCY
$144M
$4.69M 0.42%
1,000,000
– –
1
2

Similar funds

OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $1.11B AUM
JWM
JGP Wealth Management Bend, Oregon $1.11B AUM 35.22% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.11B AUM 12.31% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
AF
Arrow Financial Glens Falls, New York $1.12B AUM 24.16% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return
VFM
Viking Fund Management Minot, North Dakota $1.12B AUM 44.65% 1-Year Est. Return

Octagon Capital Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Octagon Capital Advisors held 34 positions worth $1.11B, up 23% from $904M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Octagon Capital Advisors withdrew a net $52.4M in Q2 2026, closing 7 positions and reducing 6 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $29.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Octagon Capital Advisors opened a new position in Summit Therapeutics worth $18.2M.

  • Octagon Capital Advisors's largest Q2 2026 buy was Summit Therapeutics: 1,250,000 shares worth $18.2M.
  • Octagon Capital Advisors added most to Abivax in Q2 2026, an estimated $35.8M increase.
  • Octagon Capital Advisors's biggest Q2 2026 reduction was Trevi Therapeutics, cutting an estimated $17M.
  • Octagon Capital Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $29.8M.
  • Octagon Capital Advisors's ten largest holdings make up 79% of its $1.11B portfolio in Q2 2026.
  • Octagon Capital Advisors opened 5 new positions and closed 7 in Q2 2026.
  • Octagon Capital Advisors's portfolio value rose 23% quarter-over-quarter to $1.11B.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.